| Dr Reuben Nicholas Lubka, MD | |
|
6341 University Ave Ne, Fridley, MN 55432-4946 | |
| (763) 572-5710 | |
| (763) 586-5888 |
| Full Name | Dr Reuben Nicholas Lubka |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 6341 University Ave Ne, Fridley, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154350999 | NPI | - | NPPES |
| 1008090 | Other | MN | PREFERRED ONE |
| HP10917 | Other | MN | HEALTHPARTNERS |
| 904S7LU | Other | MN | BCBS OF MN |
| 112836 | Other | MN | UCARE MN# |
| 0407201 | Other | MN | MEDICA # |
| 1754290 | Other | MN | AMERICA'S PPO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 38018 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Allina Health Home Health | Saint paul, MN | Home health agency |
| University Of Minnesota Medical Center, Fairview | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Clinics | 7113830142 | 658 |
News Archive
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."
During the Zika virus outbreak of 2015-16, public health officials scrambled to contain the epidemic and curb the pathogen's devastating effects on pregnant women. At the same time, scientists around the globe tried to understand the genetics of this mysterious virus.
bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.
Positron Emission Tomography, or PET scanning, a technique for tracing metabolic processes in the body, has been widely applied in clinical diagnosis and research spanning physiology, biochemistry and pharmacology.
› Verified 3 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."
During the Zika virus outbreak of 2015-16, public health officials scrambled to contain the epidemic and curb the pathogen's devastating effects on pregnant women. At the same time, scientists around the globe tried to understand the genetics of this mysterious virus.
bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.
Positron Emission Tomography, or PET scanning, a technique for tracing metabolic processes in the body, has been widely applied in clinical diagnosis and research spanning physiology, biochemistry and pharmacology.
› Verified 3 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."
During the Zika virus outbreak of 2015-16, public health officials scrambled to contain the epidemic and curb the pathogen's devastating effects on pregnant women. At the same time, scientists around the globe tried to understand the genetics of this mysterious virus.
bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.
Positron Emission Tomography, or PET scanning, a technique for tracing metabolic processes in the body, has been widely applied in clinical diagnosis and research spanning physiology, biochemistry and pharmacology.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Reuben Nicholas Lubka, MD 6401 University Ave Ne, Fridley, MN 55432-4341 Ph: (763) 572-5710 | Dr Reuben Nicholas Lubka, MD 6341 University Ave Ne, Fridley, MN 55432-4946 Ph: (763) 572-5710 |
News Archive
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."
During the Zika virus outbreak of 2015-16, public health officials scrambled to contain the epidemic and curb the pathogen's devastating effects on pregnant women. At the same time, scientists around the globe tried to understand the genetics of this mysterious virus.
bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.
Positron Emission Tomography, or PET scanning, a technique for tracing metabolic processes in the body, has been widely applied in clinical diagnosis and research spanning physiology, biochemistry and pharmacology.
› Verified 3 days ago
Dr. Theodore A Longinow, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 550 Osborne Rd Ne, Fridley, MN 55432 Phone: 763-236-5000 | |
Eleanor Mariano Beltran, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 7675 Madison St Ne, Fridley, MN 55432 Phone: 763-785-4500 Fax: 763-785-3314 | |
Maria Dana Tudor, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 480 Osborne Rd Ne, Suite 100, Fridley, MN 55432 Phone: 763-785-4500 Fax: 763-785-3329 | |
Joudat I. Yazigi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 550 Osborne Rd Ne, Fridley, MN 55432 Phone: 763-236-3518 | |
Uzma Ali, MBBS Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 480 Osborne Rd Ne, Suite 220, Fridley, MN 55432 Phone: 763-786-1620 Fax: 763-780-3099 | |
Dr. Dorothy L Uhlman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 Osborne Road, Suite 215, Fridley, MN 55432 Phone: 763-786-1620 Fax: 763-780-2624 |